What anti‑emetic medications and dosing are recommended for a 12‑year‑old child?

Anti-emetic Options for a 12-Year-Old Child

For a 12-year-old child, the optimal anti-emetic regimen depends on the underlying cause of vomiting, but for chemotherapy-induced nausea and vomiting (the most evidence-based context), use a combination of a 5-HT3 receptor antagonist (ondansetron 5 mg/m² or 0.15 mg/kg) plus dexamethasone, with aprepitant added for highly or moderately emetogenic chemotherapy.

Context-Specific Recommendations

For Chemotherapy-Induced Nausea and Vomiting (CINV)

The approach is stratified by emetogenic risk of the chemotherapy:

High Emetogenic Risk Chemotherapy

• Three-drug combination 1:
  • 5-HT3 antagonist (day 1 only): Ondansetron 5 mg/m² or 0.15 mg/kg IV/PO, OR Granisetron 0.01 mg/kg or 10 mcg/kg once daily
  • Dexamethasone (days 1-3 or 1-4)
  • Aprepitant: 125 mg day 1, then 80 mg days 2-3 (for ages 12-17 years) 2

Important caveat: Children require higher weight-based doses of 5-HT3 antagonists than adults due to different pharmacokinetic parameters 1, 3.

Moderate Emetogenic Risk Chemotherapy

• Two-drug combination 1:
  • 5-HT3 antagonist plus dexamethasone
  • Consider adding aprepitant for select moderate-risk agents (carboplatin, doxorubicin, irinotecan) 4

Alternative for children unable to receive dexamethasone: Use 5-HT3 antagonist plus aprepitant 5.

Low Emetogenic Risk Chemotherapy

• Single agent: Ondansetron or granisetron 5
• Dexamethasone 8 mg as alternative 1

Minimal Emetogenic Risk

• No routine prophylaxis recommended 5

For Acute Gastroenteritis

Ondansetron is the only anti-emetic with proven efficacy and safety 6, 7:

• Single oral dose: 0.15 mg/kg (maximum 8 mg)
• Benefits: Increases vomiting cessation, reduces IV rehydration needs, decreases hospitalization rates
• High-quality evidence supports its use to facilitate oral rehydration therapy 6

Avoid: Metoclopramide, dimenhydrinate, and promethazine due to inferior efficacy and significant side effects (sedation, extrapyramidal reactions) 3.

For Postoperative Nausea and Vomiting (PONV)

Ondansetron 0.1-0.15 mg/kg IV is superior to droperidol, metoclopramide, and placebo 8:

• Administer at induction or end of surgery
• Particularly effective for high-risk procedures (tonsillectomy, strabismus repair)
• Combination with dexamethasone enhances efficacy 8

Specific Drug Dosing for 12-Year-Olds

5-HT3 Receptor Antagonists

• Ondansetron: 5 mg/m² or 0.15 mg/kg IV/PO (max 8 mg per dose) 3
• Granisetron: 0.01 mg/kg or 10 mcg/kg once daily 3
• Palonosetron: 10-20 mcg/kg (note: metabolized faster in children than adults, may require higher dosing) 9

NK1 Receptor Antagonists

• Aprepitant (ages 12-17): 125 mg day 1, then 80 mg days 2-3 2
• Fosaprepitant: Can substitute for oral aprepitant on day 1 only 10

Corticosteroids

• Dexamethasone: Dosing varies 6-32 mg/m²/day in practice 9
• Reduce dexamethasone dose by 30% when combined with aprepitant (unlike 50% reduction in adults) 9

Adjunctive Agents

• Lorazepam or diphenhydramine: Useful adjuncts but NOT as single agents 1
• Olanzapine: 0.1-0.14 mg/kg/day (emerging evidence, but concerns about sedation and hyperglycemia) 9, 11

Critical Clinical Pearls

Common pitfalls to avoid:

1. Underdosing 5-HT3 antagonists: Children need higher weight-based doses than adults 1, 3
2. Using metoclopramide or phenothiazines first-line: These have inferior efficacy and higher risk of extrapyramidal side effects 3
3. Forgetting drug interactions: Monitor for QTc prolongation when combining 5-HT3 antagonists with azole antifungals, cyclosporine, or arsenic trioxide 9
4. Incorrect dexamethasone dose adjustment: Only reduce by 30% (not 50%) when adding aprepitant in children 9

Ondansetron is generally well-tolerated with mild adverse effects (headache, constipation, diarrhea) 8. The combination of 5-HT3 antagonist plus dexamethasone is more effective than either agent alone 3, 8.